According to IssueWire, “Code Pharma plans to launch an Initial Public Offering (IPO) on the NASDAQ and Switzerland’s SIX Swiss Exchange. The company had launched a limited fundraising round for international expert investors, allowing them to acquire its shares at a 20% discount with a minimum of USD 100,000 starting from November 25, 2021. All […]
IsuueWire: Code Pharma Announces a Limited Fundraising Round Read More »
Zyon Ayni, Founder and CEO of Code Pharma, updated the readers of TradeArabia about the process of their new medication: “Codivir showed great success in clinical trials and already has received emergency approvals in different countries for the treatment of coronavirus patients. Our team at Code Pharma are now initiating a multi-country phase 2 study
“The Company is Preparing for Mass Production of Codivir” | TradaArabia Read More »
On the Pressat website, it was reported that the antiviral medication Codivir recently received emergency approval for use in many countries after it was proven to be effective against the disease. Zyon Ayni, Founder and CEO of Code Pharma, said in an interview: “From day one, I saw the business and social potential. I was
Zyon Ayni: “From Day One, I Saw the Business and Social Potential” Read More »
“They found Codivir showing impressive antiviral effect, both in laboratory conditions and in phase 1 clinical trial in humans”, The website Mid East Information wrote about a new drug by Code Pharma. Code Pharma’s Founder and CEO, Zyon Ayni, quoted in the article: “Codivir showed great success in clinical trials and already has received emergency
Codivir Showing Impressive Antiviral Effect – Mid East Information Read More »
